The effect of aspirin on HbA1c is a clinically relevant consideration, particularly for people with diabetes who take low-dose aspirin for cardiovascular protection. Aspirin (acetylsalicylic acid) can influence HbA1c readings through several mechanisms — including effects on red blood cell lifespan and, at high doses, potential changes in glucose metabolism — though the impact at the standard UK cardioprotective dose of 75 mg daily is generally considered small. This article explores the evidence, identifies who is most at risk of a meaningful effect, and outlines practical guidance aligned with NICE, NHS, and MHRA recommendations for monitoring HbA1c in people taking aspirin.
Summary: The effect of aspirin on HbA1c is generally negligible at the standard UK cardioprotective dose of 75 mg daily, though haemolysis, gastrointestinal bleeding, or high-dose salicylate use can alter readings independently of true glycaemic control.
- Low-dose aspirin (75 mg daily) is not expected to cause clinically meaningful changes to HbA1c in most people.
- Aspirin-related haemolysis — most likely in G6PD deficiency — shortens red blood cell lifespan and can falsely lower HbA1c.
- Chronic gastrointestinal blood loss from aspirin may cause iron deficiency anaemia, which tends to raise HbA1c by prolonging red blood cell lifespan.
- High-dose salicylates (e.g., salsalate) have shown modest HbA1c-lowering effects in trials, but these findings do not apply to standard low-dose aspirin.
- Modern NHS HPLC and immunoassay methods are generally robust against analytical interference from aspirin.
- NICE does not recommend routine aspirin for primary cardiovascular prevention in diabetes; secondary prevention indications should follow NICE NG185 and NG128.
Table of Contents
- How Aspirin May Influence Blood Glucose and HbA1c Levels
- What the Clinical Evidence Says About Aspirin and HbA1c
- Who Is Most Likely to Be Affected: Diabetes and Aspirin Use
- NICE and NHS Guidance on Aspirin in People with Diabetes
- Practical Considerations for Monitoring HbA1c on Aspirin
- When to Speak to Your GP or Diabetes Team
- Frequently Asked Questions
How Aspirin May Influence Blood Glucose and HbA1c Levels
Aspirin can influence HbA1c through haemolysis (shortening red blood cell lifespan) or, at high doses, via insulin-sensitising effects, but neither mechanism is clinically significant at the standard UK cardioprotective dose of 75 mg daily.
Aspirin (acetylsalicylic acid) is one of the most widely used medicines in the world, prescribed at low doses for cardiovascular protection and at higher doses for pain and inflammation. Its primary mechanism of action involves the irreversible inhibition of cyclo-oxygenase (COX-1 and COX-2) enzymes, reducing the production of prostaglandins and thromboxane A2. However, aspirin's biochemical effects extend beyond platelet aggregation and inflammation, and there is some interest in how it may interact with glucose metabolism and glycated haemoglobin (HbA1c) measurements.
Worried about interactions with other medications? Speak to one of our pharmacists →
HbA1c reflects average blood glucose concentration over approximately 8–12 weeks by measuring the proportion of haemoglobin that has been glycated. In the UK, HbA1c is reported in mmol/mol (with percentage values sometimes shown alongside). Crucially, any factor that alters red blood cell (RBC) lifespan or haemoglobin turnover can influence HbA1c readings independently of actual blood glucose control.
At the low dose used for cardiovascular protection in the UK — typically 75 mg daily — aspirin is not expected to cause clinically meaningful haemolysis in most people. Haemolysis with aspirin is primarily a concern in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, in those experiencing significant gastrointestinal bleeding, or with sustained high-dose salicylate use. This is reflected in the MHRA-approved Summary of Product Characteristics (SmPC) for low-dose aspirin, which identifies G6PD deficiency and bleeding risk as specific cautions. Where haemolysis does occur, it tends to shorten RBC lifespan and can lower HbA1c values independently of actual glucose control.
Some laboratory and animal studies have suggested that high-dose salicylates may have insulin-sensitising properties, potentially through inhibition of IκB kinase-β (IKKβ), a pathway linked to insulin resistance. It is important to note that these findings relate principally to high-dose salicylate preparations (such as salsalate) that are not used in routine UK clinical practice, and should not be extrapolated to standard low-dose aspirin. The clinical significance of any glucose-metabolic effect at cardioprotective doses remains uncertain and is not established in everyday practice.
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What the Clinical Evidence Says About Aspirin and HbA1c
Clinical evidence shows no robust effect of low-dose aspirin (75 mg) on HbA1c; modest reductions seen in trials used high-dose salsalate, which is not standard UK practice.
The clinical evidence examining the effect of aspirin on HbA1c is mixed and, in many cases, limited by small sample sizes, varying doses, and heterogeneous study populations. Some observational studies and randomised controlled trials have suggested that high-dose salicylates — notably salsalate, studied in trials such as TINSAL-T2D — may produce modest reductions in fasting blood glucose and HbA1c in people with type 2 diabetes. These findings are thought to reflect anti-inflammatory and insulin-sensitising effects at high salicylate concentrations. However, salsalate and other high-dose salicylate preparations are not standard treatments in the UK, and these results should not be applied to low-dose aspirin.
At the low doses commonly used for cardiovascular prevention in the UK — typically 75 mg daily — there is no robust evidence of a clinically meaningful effect on HbA1c. Studies examining low-dose aspirin have generally found no statistically significant change in HbA1c, and any theoretical glucose-lowering effect is considered dose-dependent and unlikely to be relevant at cardioprotective doses.
Regarding analytical interference: older assay technologies were susceptible to interference from acetylated haemoglobin, potentially producing falsely low HbA1c readings. Modern HPLC and immunoassay methods used in NHS laboratories, which are aligned with IFCC standardisation, are generally robust against this interference. RCPath and the Association for Clinical Biochemistry (ACB) provide guidance on factors affecting HbA1c reliability. Clinicians should be aware that discordant results — where HbA1c appears inconsistent with self-monitored glucose readings or clinical findings — warrant discussion with the laboratory to confirm the assay method used and to consider whether analytical or biological factors may be contributing.
Who Is Most Likely to Be Affected: Diabetes and Aspirin Use
People with G6PD deficiency, iron deficiency anaemia, haemoglobinopathy, or chronic kidney disease are most likely to have aspirin-related changes in HbA1c accuracy, due to altered red blood cell turnover.
People with diabetes — both type 1 and type 2 — are among the most frequent users of low-dose aspirin, given their elevated cardiovascular risk. This overlap means that understanding the potential effect of aspirin on HbA1c is particularly relevant in diabetes care. For the vast majority of people taking 75 mg aspirin daily, the effect on HbA1c is unlikely to be clinically significant.
It is important to understand the directionality of HbA1c changes in different clinical situations:
-
Haemolytic states (including aspirin-related haemolysis in G6PD deficiency or significant bleeding) shorten RBC lifespan and tend to lower HbA1c, potentially masking poor glycaemic control.
-
Iron deficiency anaemia — which can result from chronic aspirin-related gastrointestinal blood loss — tends to raise HbA1c by prolonging RBC lifespan, potentially overstating glycaemic control.
-
Chronic kidney disease (CKD) is associated with reduced RBC survival and may lower HbA1c, though effects are variable.
Those in whom aspirin is most likely to influence HbA1c results include:
-
People with G6PD deficiency, who are at specific risk of haemolysis with salicylates, as noted in the aspirin SmPC.
-
People taking higher doses of aspirin (e.g., for inflammatory conditions), where both glucose-lowering and haemolytic effects are more pronounced.
-
Individuals with conditions independently affecting RBC turnover, such as haemolytic anaemia, iron deficiency anaemia, haemoglobinopathy, or CKD, where any aspirin-related effect may compound existing inaccuracies in HbA1c measurement (as acknowledged in NICE NG28).
-
Older adults, who may be more susceptible to aspirin-induced gastrointestinal blood loss, leading to iron deficiency and altered RBC lifespan.
Awareness of these interactions is valuable for diabetes teams when interpreting HbA1c results that appear unexpectedly low or high, or inconsistent with the patient's reported symptoms or self-monitored glucose data.
NICE and NHS Guidance on Aspirin in People with Diabetes
NICE does not recommend routine low-dose aspirin for primary cardiovascular prevention in diabetes; for secondary prevention, clopidogrel is preferred after stroke or TIA, with aspirin recommended post-myocardial infarction per NICE NG185.
NICE guidance does not recommend routine low-dose aspirin for the primary prevention of cardiovascular disease in people with type 1 or type 2 diabetes. This position reflects evidence that the bleeding risks associated with aspirin — particularly gastrointestinal haemorrhage — may outweigh the cardiovascular benefits in individuals who have not yet experienced a cardiovascular event. NICE NG28 (Type 2 diabetes in adults) and NICE NG17 (Type 1 diabetes in adults) both reflect this cautious approach to primary prevention.
For secondary prevention — in people with established cardiovascular disease — antiplatelet therapy remains a cornerstone of management. Low-dose aspirin is recommended following myocardial infarction and acute coronary syndromes, consistent with NICE NG185. However, for long-term secondary prevention after ischaemic stroke or transient ischaemic attack (TIA), NICE NG128 recommends clopidogrel as the preferred first-line antiplatelet agent, with aspirin reserved for those in whom clopidogrel is unsuitable or for specific combination regimens. Clinicians should refer to the relevant NICE guidance when determining the appropriate antiplatelet regimen for individual patients.
Neither NICE nor NHS England guidance specifically requires routine changes to HbA1c monitoring because of aspirin use. However, NICE NG28 acknowledges that certain conditions — including haemoglobinopathies, haemolytic anaemia, and other factors affecting RBC turnover — can render HbA1c unreliable. In such circumstances, alternative measures such as fructosamine or continuous glucose monitoring (CGM) may be considered. Clinicians should apply this principle when aspirin use, in the context of anaemia or bleeding, is suspected of influencing HbA1c accuracy.
NICE NG28 recommends measuring HbA1c every 3–6 months until levels and treatment are stable, then every 6 months thereafter. This schedule forms part of the NHS annual diabetes review and structured care pathway.
| Clinical Scenario | Aspirin Dose / Context | Effect on HbA1c | Mechanism | Clinical Action |
|---|---|---|---|---|
| Standard cardiovascular prevention | 75 mg daily (low dose) | No clinically meaningful effect expected | Insufficient dose to cause haemolysis or significant glucose-metabolic effect | Routine HbA1c monitoring; no adjustment required |
| G6PD deficiency | Any dose of aspirin | Falsely low HbA1c; may mask poor glycaemic control | Aspirin-induced haemolysis shortens RBC lifespan | Document G6PD status; consider fructosamine or CGM |
| Aspirin-related gastrointestinal blood loss | Any dose; risk higher with prolonged use | Falsely raised HbA1c; may overstate poor control | Iron deficiency anaemia prolongs RBC lifespan | Investigate anaemia; check ferritin; review aspirin indication |
| High-dose salicylate use (e.g., salsalate) | High-dose; not standard UK practice | Modest reduction in HbA1c and fasting glucose reported (TINSAL-T2D) | IKKβ inhibition; anti-inflammatory insulin-sensitising effect | Do not extrapolate to low-dose aspirin; consult specialist |
| Concurrent haemoglobinopathy or CKD | Any dose | HbA1c unreliable; aspirin may compound existing inaccuracy | Altered RBC turnover independent of aspirin; effects additive | Per NICE NG28: consider fructosamine or CGM as alternatives |
| Analytical interference (older assays) | Any dose | Falsely low HbA1c due to acetylated haemoglobin | Acetylation of haemoglobin interfered with older assay methods | Modern NHS HPLC/immunoassay (IFCC-aligned) methods are robust; confirm assay with laboratory if in doubt |
| Discordant HbA1c vs. self-monitored glucose | Any dose; especially high-dose or with anaemia | Result may not reflect true glycaemic control | Biological or analytical interference from aspirin-related effects | Discuss with laboratory; consider fructosamine or CGM per RCPath/ACB guidance |
Practical Considerations for Monitoring HbA1c on Aspirin
Routine HbA1c monitoring can continue unchanged for most patients on 75 mg aspirin daily; fructosamine or CGM should be considered when anaemia, haemoglobinopathy, or discordant results raise doubt about HbA1c reliability.
For most patients taking low-dose aspirin (75 mg daily), routine HbA1c monitoring can continue as normal, and no specific adjustments to testing frequency or interpretation are required. The potential influence of aspirin on HbA1c at this dose is generally considered too small to alter clinical decision-making. Standard NHS laboratory methods are designed to minimise analytical interference, and results should be interpreted in the context of the full clinical picture.
However, there are specific situations where clinicians and diabetes teams should exercise additional caution:
-
Unexpectedly low or high HbA1c results that do not align with the patient's self-monitored blood glucose readings, reported symptoms, or previous trends should prompt further investigation and discussion with the laboratory.
-
Patients on sustained high-dose salicylates (e.g., for inflammatory conditions) may warrant closer scrutiny of HbA1c results, as both haemolytic and potential glucose-metabolic effects are more plausible at higher doses. Note that a brief course of 300 mg aspirin (e.g., for an acute cardiovascular event) is unlikely to affect an HbA1c result reflecting 8–12 weeks of glucose exposure.
-
Concurrent conditions such as anaemia, haemoglobinopathy, G6PD deficiency, or renal impairment should always be documented, as these independently affect HbA1c reliability (see RCPath/ACB guidance).
-
In cases of genuine uncertainty, fructosamine testing (which reflects average glucose over approximately 2–3 weeks and is unaffected by RBC lifespan) may provide a useful alternative. However, fructosamine is itself affected by conditions altering serum protein turnover, such as nephrotic syndrome or significant liver disease, and its use should be guided by clinician–laboratory discussion. CGM may also provide a more detailed picture of glycaemic patterns.
Open communication between the patient, their GP, and the diabetes team is essential. Patients should be encouraged to report any new symptoms — including unusual bruising, black or tarry stools, or signs of anaemia such as fatigue and breathlessness — which could indicate aspirin-related blood loss and secondary effects on HbA1c. Suspected side effects from aspirin can be reported via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk).
When to Speak to Your GP or Diabetes Team
Contact your GP or diabetes team if HbA1c results are inconsistent with home glucose readings, or if you develop symptoms of anaemia or gastrointestinal bleeding; seek emergency care for dark stools or vomiting blood.
If you are taking aspirin and have diabetes, it is important to attend your regular diabetes reviews. NICE recommends HbA1c testing every 3–6 months until your glucose levels and treatment are stable, then every 6 months as part of your NHS annual diabetes review. In most cases, aspirin will not significantly affect your HbA1c result, and your care team will interpret your results alongside your full medical history.
You should contact your GP or diabetes team if you notice any of the following:
-
HbA1c results that seem inconsistent with how you have been feeling, or that differ significantly from your home blood glucose or CGM readings.
-
Symptoms of anaemia, such as persistent tiredness, pallor, shortness of breath, or dizziness, which could suggest aspirin-related gastrointestinal bleeding affecting your blood count and, in turn, your HbA1c.
-
Any change in your aspirin dose — for example, if you have been started on a higher dose for a new condition — as this may warrant a review of your diabetes monitoring plan.
Seek urgent medical attention if you experience dark or tarry stools, vomiting blood, or unexplained severe abdominal pain. These are potential signs of serious gastrointestinal bleeding: call 999 or go to your nearest A&E department immediately. For concerns about bleeding or anaemia that are not immediately life-threatening, contact NHS 111 or your GP urgently.
It is also worth raising any concerns about your aspirin prescription at your next medication review. Your GP or pharmacist can advise whether your current dose remains appropriate and whether any adjustments to your diabetes monitoring are needed. Never stop taking prescribed aspirin without first seeking medical advice, as doing so could increase your risk of a serious cardiovascular event. If you think aspirin has caused a side effect, you can report this to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
Frequently Asked Questions
Does low-dose aspirin (75 mg) affect HbA1c results?
For most people, low-dose aspirin (75 mg daily) does not cause a clinically meaningful change in HbA1c. Any influence on HbA1c is more likely in those with G6PD deficiency, iron deficiency anaemia from gastrointestinal bleeding, or other conditions that alter red blood cell lifespan.
Can aspirin cause a falsely low HbA1c reading?
Aspirin can cause haemolysis in susceptible individuals — particularly those with G6PD deficiency — which shortens red blood cell lifespan and may produce a falsely low HbA1c, potentially masking poor glycaemic control. Modern NHS laboratory assays are generally robust against direct analytical interference from aspirin.
Should people with diabetes stop taking aspirin if their HbA1c seems inaccurate?
Never stop prescribed aspirin without medical advice, as this could increase the risk of a serious cardiovascular event. If HbA1c results appear inconsistent with home glucose readings or clinical symptoms, discuss this with your GP or diabetes team, who can investigate further and consider alternative monitoring methods such as fructosamine or CGM.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
